证券代码：600329 证券简称：达仁堂 编号：临 2023-036 号 津药达仁堂集团股份有限公司 关于召开 2023 年半年报业绩说明会暨参加天津辖区 上市公司投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 9 月 5 日（星期二）下午 15:00—16:40 会议召开地点：全景路演（http: //rs.p5w.net） 会议召开方式：网络互动 投资者可于 2023 年 9 月 1 日（星期五）17:00 前预先提出所 关 注 的 问 题 并 以 电 子 邮 件 方 式 发 送 到 公 司 邮 箱 （drt600329@163.com）。公司将在说明会上对投资者普遍关 注的问题进行回答。 一、说明会类型 津药达仁堂集团股份有限公司（以下简称"公司"）已于 2023 年 8 月 15 日发布了 2023 年半年度报告（详见上海证券交易所网站 www.sse.com.cn）。为便于广大投资者更深入全面地了解公司经营业 绩等情况，公司定于 2023 年 ...

Financial Performance - Revenue for the first half of 2023 reached RMB 4,088,308,842.02, an increase of 8.31% compared to the same period last year[16] - Net profit attributable to shareholders of the listed company was RMB 722,491,488.60, a significant increase of 54.12% year-on-year[16] - Basic earnings per share (EPS) for the reporting period were RMB 0.94, up 54.10% compared to the same period last year[17] - Weighted average return on equity (ROE) increased by 3.22 percentage points to 10.54%[17] - Operating cash flow increased by 37.48% to RMB 122,433,735.29[16] - Revenue increased by 8.31% to 4,088,308,842.02 yuan compared to the same period last year[61] - Net profit attributable to shareholders of the parent company was 722 million yuan, a significant increase of 54.12% year-on-year[36] - Operating revenue for the first half of 2023 reached 4,088,308,842.02 RMB, up from 3,774,763,809.73 RMB in the same period last year[144] - Net profit attributable to parent company shareholders reached 722,491,488.60 RMB, compared to 468,785,051.09 RMB in the same period last year[146] - Basic earnings per share (EPS) rose to 0.94 RMB from 0.61 RMB in the previous year[147] - Total comprehensive income reached 715,838,377.52 RMB, up from 476,925,168.97 RMB in the same period last year[147] - Sales revenue from goods and services increased to 4,159,478,789.36 in H1 2023, up from 3,438,491,278.73 in H1 2022, reflecting a 20.96% growth[152] - Net cash flow from operating activities rose to 122,433,735.29 in H1 2023, compared to 89,054,915.47 in H1 2022, indicating a 37.47% increase[152] - Comprehensive income for the period was RMB 715.8 million, driven by a net profit of RMB 722.5 million[158] - Total comprehensive income for the period was RMB 81.7 million, with a net profit contribution of RMB 85.1 million[160] - The comprehensive income for the period was RMB 757,671,375.90, driven by a net profit of RMB 756,300,446.31[162] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 10,364,005,536.89, an increase of 2.04% compared to the end of the previous year[16] - Net assets attributable to shareholders of the listed company decreased by 2.90% to RMB 6,332,314,528.74[16] - Total assets increased to 10,364,005,536.89 RMB as of June 30, 2023, compared to 10,156,982,039.41 RMB at the end of 2022[138][139][140] - Cash and cash equivalents decreased to 2,103,958,426.22 RMB from 2,882,523,954.61 RMB, a decline of 27%[138] - Accounts receivable increased by 17.2% to 2,515,042,678.31 RMB from 2,146,213,416.31 RMB[138] - Inventory rose by 17.4% to 1,677,798,658.15 RMB from 1,429,451,795.45 RMB[138] - Short-term borrowings surged by 421.6% to 530,169,300.45 RMB from 101,638,515.28 RMB[139] - Total liabilities increased to 3,974,356,989.02 RMB, up 10.2% from 3,605,028,900.58 RMB[139][140] - Shareholders' equity decreased by 2.5% to 6,389,648,547.87 RMB from 6,551,953,138.83 RMB[140] - Long-term investments grew by 11.8% to 849,612,344.04 RMB from 760,192,827.41 RMB[138] - Fixed assets declined by 3.8% to 1,084,531,897.41 RMB from 1,127,742,589.56 RMB[138] - Intangible assets increased by 17.3% to 329,797,889.45 RMB from 281,127,790.71 RMB[139] - Total assets increased to 8,998,033,329.54 RMB, up from 8,901,211,797.61 RMB in the previous period[142] - Long-term equity investments rose to 2,349,217,735.84 RMB, compared to 2,296,458,142.20 RMB previously[142] - Total liabilities increased to 2,314,470,286.33 RMB, up from 2,094,478,021.81 RMB previously[143] - Shareholders' equity decreased to 6,683,563,043.21 RMB, down from 6,806,733,775.80 RMB in the previous period[143] - Total owner's equity at the end of the period decreased by RMB 162.3 million to RMB 6.39 billion, compared to the beginning of the period[158][159] - Owner's equity decreased by RMB 189.1 million due to a reduction in capital and retained earnings[158] - Capital reserve decreased by RMB 72.7 million, primarily due to share-based payments and other adjustments[158] - Retained earnings at the end of the period stood at RMB 4.13 billion, down from RMB 4.26 billion at the beginning[158] - The company's total owner's equity at the end of the period was RMB 6,595,494,148.73, with a net increase of RMB 144,131,574.66 compared to the previous period[161] - The company's total owner's equity at the beginning of the period was RMB 6,806,733,775.80, with a decrease of RMB 123,170,732.59 during the period[162] - The company's total owner's equity at the end of the period was RMB 6,683,563,043.21, reflecting a decrease from the beginning balance[163] - The company's capital reserve increased by RMB 3,576,387.27 due to owner contributions and reductions in capital[165] - The company's total owner's equity at the end of the period was RMB 6,499,139,607.20, reflecting a decrease from the beginning balance[165] Cash Flow - Operating cash flow increased by 37.48% to RMB 122,433,735.29[16] - Investment cash flow decreased by 193.63% to -487,182,638.67 RMB, mainly due to reduced cash receipts from investments[61] - Net cash flow from operating activities rose to 122,433,735.29 in H1 2023, compared to 89,054,915.47 in H1 2022, indicating a 37.47% increase[152] - Cash outflow for investments surged to 645,100,234.89 in H1 2023, up from 133,395,927.14 in H1 2022, a significant 383.60% rise[153] - Net cash flow from financing activities improved to -344,434,848.42 in H1 2023, from -381,537,177.75 in H1 2022, showing a 9.73% reduction in negative cash flow[153] - Cash and cash equivalents at the end of the period decreased to 2,001,527,474.76 in H1 2023, down from 2,511,049,911.58 in H1 2022, a 20.29% decline[153] - Parent company's net cash flow from operating activities fell to 305,253,953.34 in H1 2023, from 1,092,761,924.19 in H1 2022, a 72.07% decline[156] - Parent company's cash outflow for investments increased to 1,597,735,245.83 in H1 2023, up from 1,310,580,368.13 in H1 2022, a 21.91% rise[156] - Parent company's net cash flow from financing activities worsened to -697,139,366.90 in H1 2023, from -363,706,187.30 in H1 2022, a 91.68% increase in negative cash flow[157] - Parent company's cash and cash equivalents at the end of the period decreased to 1,682,541,310.01 in H1 2023, down from 2,087,439,919.72 in H1 2022, a 19.40% decline[157] Business Operations - The company's pharmaceutical manufacturing sector includes well-known products such as Su Xiao Jiuxin Wan and Jing Wan Hong Ointment, with a focus on traditional Chinese medicine[23] - The pharmaceutical commercial sector covers Tianjin and extends nationwide, with Tianjin Zhongxin Pharmaceutical Co., Ltd. being a leading drug distributor in Tianjin[24] - The company's procurement model involves electronic systems for supplier selection and has established GAP planting bases for herbs like Chuanxiong and Honeysuckle[25] - Production follows a "sales-driven" model with a 90-day rolling demand approval process to ensure supply and reasonable inventory[26] - Sales strategies include partnerships with leading commercial enterprises and a focus on academic and professional promotion, with efforts to expand online sales through B2B, B2C, and O2O models[27] - The company expanded its digital presence by deploying AI technologies like AIGC and ChatGPT across platforms such as Ali, JD, and TikTok[50] - 27 key research projects were focused on core products like Suxiao Jiuxin Pill and Qingyan Drop Pill, collaborating with institutions like the University of Macau and Tianjin University of Traditional Chinese Medicine[52] - The company completed the preparation of 4 health wine samples and advanced several health projects to the prescription confirmation and sample preparation stages[53] - A digital strategy for 2023-2027 was initiated, with the first phase of the IT strategy focusing on business unit empowerment[55] - The company expanded its team by over 200 employees, with a focus on frontline positions and optimizing performance management[59] - The company's "Qingyan Dripping Pills" were listed in 24 provinces and distributed to over 400 chain stores, with development in more than 2,000 medical terminals[43] - The company's "Suxiao Jiuxin Pill" was included in the "Chinese Guidelines for the Management of Hypertension in the Elderly"[45] - The company's "Tongmai Yangxin Pill" was included in the "Expert Consensus on Drug Therapy Management Pathways for Patients with Coronary Atherosclerotic Heart Disease"[45] - The company's "Bianqi Capsule" was included in the "Chinese Expert Guidelines for Non-Opioid Analgesic Drug Treatment of Chronic Musculoskeletal Pain"[45] Industry and Market Conditions - In 2023 H1, China's pharmaceutical manufacturing industry saw a 2.9% decrease in revenue to RMB 12,496.0 billion and a 17.1% drop in profit to RMB 1,794.5 billion[28] - National policies strongly support the development of traditional Chinese medicine, emphasizing its role in disease prevention, treatment, and rehabilitation[29] - Rising costs of traditional Chinese medicine materials and energy have increased pressure on cost control, with the China Traditional Chinese Medicine Price Index rising from 1738.89 in June 2022 to 2144.72 in June 2023[30] - The average price reduction in the second batch of centralized procurement for traditional Chinese medicine was 49.36%, significantly impacting pharmaceutical companies' pricing power[31] - The average price reduction in the second batch of centralized procurement of traditional Chinese medicines in Hubei was 49.36%, reflecting the increasing uncertainty for pharmaceutical companies due to the normalization of centralized procurement policies[75] - The price of traditional Chinese medicinal materials has increased significantly, rising from 1738.89 points in June 2022 to 2144.72 points in June 2023, reflecting a 23.3% year-over-year increase[77] - The company faces potential risks of rising labor costs due to increased employee compensation and social security levels[78] - The pharmaceutical market may experience limited growth in bid prices due to increased buyer bargaining power, particularly from medical insurance payments[79] - The pharmaceutical industry is facing intensified competition in retail channels, with a clearer path towards the separation of medical and pharmaceutical services[80] - New drug development is characterized by high investment, long cycles, and significant risks, with increasing technical review standards and potential delays or failures in market entry[81] - Regulatory requirements for drug quality and safety have been strengthened, with stricter standards for traditional Chinese medicine materials and higher expectations for drug vigilance[83] Corporate Governance and Shareholder Information - The company's A-share stock code is 600329, listed on the Shanghai Stock Exchange, and its S-share stock code is T14, listed on the Singapore Exchange[15] - The company has undergone several changes in its board and executive team, including the resignation of key personnel and the appointment of a new CFO[86] - No profit distribution or capital reserve conversion plan was proposed for the first half of the year[87] - The company has implemented a 2019 A-share restricted stock incentive plan, with multiple adjustments and cancellations of restricted stocks for non-compliant incentive objects[88][89] - The company's controlling shareholder, Tianjin Pharmaceutical Group, has committed to avoiding competition with the company and ensuring fair market principles in related transactions[99] - Tianjin Pharmaceutical Group commits to transferring over 50% equity of its pharmaceutical commercial business to an independent third party or injecting related businesses into the listed company platform by December 31, 2024, to resolve potential competition issues[101] - Tianjin Pharmaceutical Group will ensure compliance with state-owned asset management regulations and obtain necessary approvals from the Tianjin State-owned Assets Supervision and Administration Commission to resolve potential competition issues[101] - Tianjin Pharmaceutical Group promises to compensate the company for any losses incurred due to the Jinyao Amino Acid litigation[103] - Tianjin Bohai State-owned Assets Management Company commits to avoiding related-party transactions with the company and ensuring fair and reasonable transaction prices if unavoidable[102] - Tianjin Bohai State-owned Assets Management Company pledges to reduce and avoid competition by not engaging in or supporting businesses that compete with the company's main operations[102] - The company appointed Zhong Shen Hua Certified Public Accountants as its domestic auditor and FKT Certified Public Accountants as its overseas auditor for 2023, pending shareholder approval[104] - Total related-party transactions amounted to RMB 267.95 million, accounting for 9.755% of total transactions[108] - The largest related-party transaction was with Jinping Pharmaceutical Co., Ltd., amounting to RMB 93.89 million, accounting for 4.238% of similar transactions[105] - Sales to related parties totaled RMB 70.89 million, representing 1.734% of total sales[107] - The company engaged in significant transactions with its parent company's subsidiaries, including Jinping Pharmaceutical Co., Ltd. and Tianjin Hongrentang Pharmaceutical Co., Ltd.[105][107] - The company's transactions with its parent company's subsidiaries were primarily for the purchase and sale of goods, with pricing based on market rates[105][107] - The company's related-party transactions were predominantly settled in cash[105][107] - The company did not report any significant asset acquisitions, equity acquisitions, or sales during the reporting period[108] - No significant changes or progress were reported in previously disclosed joint investment-related transactions[109] - The company renewed the "Financial Services Agreement" with Tianjin Pharmaceutical Group Finance Co., Ltd., a related transaction that has been disclosed in temporary announcements since 2017[110] - The company's initial balance with Chengdu Zhongxin Pharmaceutical Co., Ltd. was 3,697,782.00 RMB, with no changes during the period, maintaining the same ending balance[111] - Tianjin Hongrentang Pharmaceutical Co., Ltd. had an initial balance of 1,059,900.00 RMB, which was fully reduced during the period, resulting in an ending balance of 0[111] - Tianjin Taiping Zhenhua Pharmacy Co., Ltd. had an initial balance of 66,690.00 RMB, which was fully reduced during the period, resulting in an ending balance of 0[112] - Tianjin Taiping Xiangyun Pharmaceutical Co., Ltd. had an initial balance of 642,988.64 RMB, with an increase of 5,473,315.62 RMB during the period, resulting in an ending balance of 6,116,304.26 RMB[112] - Tianjin Pharmaceutical Group Zhongjiankangda Medical Technology Co., Ltd. had an initial balance of 16,067.20 RMB, with no changes during the period, maintaining the same ending balance[112] - Victorch Meditek, Inc. had an initial balance of 589,483.54 RMB, with an increase of 9,969.54 RMB during the period, resulting in an ending balance of 599,453.08 RMB[112] - The company's deposit business with Tianjin Pharmaceutical Group Finance Co., Ltd. had an initial balance of 590,758,195.72 RMB, with total deposits of 18,820,869,644.39 RMB and total withdrawals of 18,822,861,635.55 RMB, resulting in an ending balance of 588,766,204.56 RMB[115] - The deposit interest rate range for the company's deposit business with Tianjin Pharmaceutical Group Finance Co., Ltd. was between 0.42% and 2.25%[115] - Loan business with Tianjin Pharmaceutical Group Finance Co., Ltd. (a related party) had a loan amount of 600,000,000 RMB, with an interest rate range of 3.68%-3.75%, and an ending balance of 327,890,000 RMB[116] - Total loan issuance during the period was 300,000,000 RMB, with repayments of 10,330,495.28 RMB, resulting in an ending balance of 327,890,000 RMB[116] - The company's total guarantee amount (including guarantees for subsidiaries) was 299,453,458.70 RMB, accounting for 4.73% of the company's net assets[121] - The company's total guarantee amount

2023 年第一季度报告 单位：元 币种：人民币 证券代码：600329 证券简称：达仁堂 津药达仁堂集团股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|------------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增 减变动幅度 (%) | | 营业收入 | 2,154,405,776.85 | ...

2022 年年度报告 津药达仁堂集团股份有限公司 2022 年年度报告 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 信永中和会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人张铭芮、主管会计工作负责人牛胜芳及会计机构负责人（会计主管人员）高娜声 明：保证年度报告中财务报告的真实、准确、完整。 1 / 228 2022 年年度报告 重要提示 公司代码：600329 公司简称：达仁堂 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露年度报告的真实性、准确性和完整性 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经信永中和会计师事务所审计（中国准则），本公司2022年度实现净利润按中国会计准则核 算为835,768,249.30元，公司年初累计未分配利润3,787,873,522.34元，2022年年度实施利润分 配共计分配股利386,721,538.0 ...

2021 年年度报告 公司代码：600329 公司简称：中新药业 天津中新药业集团股份有限公司 2021 年年度报告 1 / 216 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 信永中和会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人张铭芮、主管会计工作负责人牛胜芳及会计机构负责人（会计主管人员）欧阳剑 声明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经信永中和会计师事务所审计（中国准则），本公司2021年度实现净利润按中国会计准则核 算为771,859,541.02元，公司年初累计未分配利润3,247,986,904.12元，2021年年度实施利润分 配共计分配股利231,972,922.80元，至此，本年累计可供全体股东分配的利润为3,787,873,522.34 元。 2021年度末，公司拟进行利润分配，具体利 ...